My PD-L1 Is Low or Negative — Does That Mean Immunotherapy Will Not Work?

No — a low or negative PD-L1 score does not automatically rule out immunotherapy. PD-L1 is one biomarker among several your oncology team weighs together, and a proportion of patients with low or negative scores still respond to checkpoint inhibitors, particularly in combination regimens or when other markers such as MSI-H or dMMR are favourable. It is a probability signal, not a yes-or-no switch.

PD-L1 testing itself is coordinated through partner pathology laboratories and reported back as a percentage or score on your biopsy report. Your oncologist reads this number alongside your cancer type, stage, prior treatments and any other biomarker results available — no single figure decides eligibility on its own, and no test can guarantee a response either way.

Exact cut-offs differ by cancer type and by the specific PD-L1 assay used (commonly 22C3, 28-8 or SP263 antibody clones), and labs may present bands slightly differently. This table explains general terminology only — please ask your oncologist which assay, cut-off and band apply to your own report. (Source: NCCN and ASCO immunotherapy biomarker guidance, reviewed August 2026.)

Even patients with a low or negative PD-L1 score can respond to checkpoint inhibitors, because PD-L1 expression is an imperfect proxy for how a tumour actually behaves against the immune system. Sampling variability, tumour heterogeneity, and biology captured by other markers such as MSI-H, dMMR or tumour mutational burden can all point toward a possible response even when PD-L1 alone looks unfavourable.

This is why oncology guidelines from bodies such as NCCN and ASCO describe PD-L1 as a helpful but incomplete predictor rather than a strict eligibility gate. In several cancer types, immunotherapy — often combined with chemotherapy — remains an approved option even for PD-L1-negative tumours, with response typically lower than in PD-L1-high tumours but not absent. Your tumour board reviews the complete picture before ruling anything in or out.

This page explains general terminology and biology; it is not an interpretation of any individual patient's report. Only your treating oncologist, with your full case in front of them, can say what your specific result means for you.

• Cancer type and histology — PD-L1 cut-offs and their meaning differ substantially between lung, gastric, cervical, urothelial and other cancers.
• MSI-H / dMMR status — a tumour-agnostic marker that can support immunotherapy use independent of the PD-L1 result.
• Tumour mutational burden (TMB) — a separate genomic marker sometimes used alongside PD-L1 in eligibility discussions.
• Stage and prior treatment — whether immunotherapy is being considered first-line, after chemotherapy, or in combination changes how PD-L1 is weighed.
• Overall fitness and comorbidities — general health and organ function affect whether checkpoint-inhibitor side effects can be safely managed and monitored.
• Tumour board discussion — at CION, every case is reviewed by a multidisciplinary team, not decided from a single report value.

No single factor above decides eligibility alone — they are weighed together against current NCCN, ASCO and ESMO guidance, and no outcome is guaranteed either way.

1. 1

   Confirm the full biomarker panel

   Your oncologist checks whether MSI-H/dMMR, tumour mutational burden or other relevant markers were tested alongside PD-L1, since a low PD-L1 result rarely stands alone in a treatment decision.

2. 2

   Tumour board review

   Your case is discussed by a multidisciplinary team weighing cancer type, stage, prior treatment and the complete biomarker picture together, not any single score in isolation.

3. 3

   Discuss combination approaches

   In several cancers, checkpoint inhibitors combined with chemotherapy remain an option even with a low or negative PD-L1 score — your oncologist will explain if this applies to your case.

4. 4

   Consider a second opinion

   Because PD-L1 interpretation is nuanced, a second, doctor-led review of your reports before finalising a treatment plan is a reasonable and common step, not a sign of distrust in your first team.

• MSI-High and dMMR: What These Results Mean for Immunotherapy — the tumour-agnostic marker that can matter even when PD-L1 looks unfavourable.
• Which Biomarker Tests Do You Actually Need — and What Do They Cost? — how to sequence PD-L1, MSI and TMB testing without paying for tests you don't need.
• Is Biomarker Testing Covered by Insurance or Government Schemes? — what's reimbursed and how to claim it before you pay out of pocket.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION evaluates eligibility and delivers treatment.

This page explains general PD-L1 testing terminology and does not interpret your individual report. PD-L1 and related biomarker testing are coordinated through partner pathology laboratories. Always discuss your specific results with your treating oncologist.

Thousands of families have asked the same question about their reports

A confusing biomarker report is common, not a sign you've missed something. Our team can walk you through it in plain language, at no cost.